UNSPSC 51112101: Denileukin diftitox

This classification denotes an immunotoxin and fusion toxin with the molecular formula C2560H4042N678O799S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25E79B5CTM, more generally known as denileukin diftitox. European Medicines Agency schedules denileukin diftitox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06975MIG. The term DENILEUKIN DIFTITOX is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40.

As of Q4 2014, DENILEUKIN DIFTITOX remains the US FDA Preferred Term for this commodity.

UNSPSC 51112101 Denileukin diftitox is a Commodity code representing a specific pharmaceutical product — a recombinant fusion protein used in cancer immunotherapy — that state and local health agencies procure through pharmacy benefit programs, health plan contracting, and direct manufacturer relationships. The code sits within state pharmaceutical procurement activity, where health agencies, Medicaid programs, and employee health plans source specialty pharmaceuticals either through traditional pharmacy benefit managers and group purchasing organizations or, increasingly, through direct-to-manufacturer contracting models that aim to reduce intermediation costs and improve fulfillment speed. State health and human services departments drive solicitation activity under this code, purchasing on behalf of state employees, Medicaid beneficiaries, and other covered populations.

The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targets vendors experienced with direct contracting for self-insured employers and health plans in government sectors, with capacity to negotiate net pricing models without rebates and implement value-based or outcomes-based agreements. This preliminary market intelligence activity signals Texas HHS's intent to reshape its pharmacy procurement strategy away from traditional PBM and GPO intermediaries toward direct manufacturer relationships, though no formal RFP, award value, or implementation timeline has been announced. The RFI represents exploratory procurement activity designed to inform the state's future strategy before issuing binding solicitations with defined financial and temporal parameters.